NCCN Joins International Meeting to Improve Cancer Care in the Middle East and North Africa Region PressReach · Jan 13, 2025
Timberlyne Therapeutics Launches with a $180 Million Series A Financing to Advance CM313, a Potentially Best-in-Class Anti-CD38 Monoclonal Antibody, for Diseases of High Unmet Medical Needs PressReach · Jan 13, 2025
Astraveus Announces World First End-to-End Production of CAR-T Cells Using Microfluidic Technology PressReach · Jan 9, 2025
Commit Biologics appoints accomplished R&D executive, Dr Janine Schuurman, to its Board of Directors PressReach · Jan 8, 2025
China's National Medical Products Administration (NMPA) Approves PADCEV™ in combination with KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Bladder Cancer PressReach · Jan 8, 2025
Clarivate Identifies Eleven Potential Blockbuster and Transformative Drugs in Annual Drugs to Watch Report PressReach · Jan 8, 2025
